Form 4 Sagimet Biosciences Inc. For: Nov 16 Filed by: Happel David
Sagimet Biosciences Inc. (SGMT)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024GlobeNewswire
- Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & HepatologyGlobeNewswire
- Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.MarketBeat
- Sagimet soars on FDA breakthrough therapy designation for its liver disease treatment [Seeking Alpha]Seeking Alpha
- Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASHGlobeNewswire
SGMT
Earnings
- 8/14/24 - Beat
SGMT
Sec Filings
- 8/27/24 - Form EFFECT
- 8/16/24 - Form 8-K
- 8/15/24 - Form S-3
- SGMT's page on the SEC website